ESMO News
Refine search
Biotechnology
Germany-based Immatics has this month announced updated clinical data from its PRAME-directed TCR T-cell therapy, anzu-cel (anzutresgene autoleucel, IMA203), in 16 patients with metastatic uveal melanoma. 3 November 2025
Biotechnology
US biotech Exelixis has announced detailed results from STELLAR-303, a global Phase III pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq) versus regorafenib in previously-treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). 20 October 2025
Pharmaceutical
Swiss pharma giant Novartis yesterday presented positive new Pluvicto (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025. 20 October 2025
Biotechnology
Positive results have been presented on Datroway (datopotamab deruxtecan) from the TROPION-Breast02 Phase III trial at the ESMO Annual Meeting in Berlin, Germany. 19 October 2025
Biotechnology
More positive data has been presented at the ESMO Congress on Enhertu (trastuzumab deruxtecan), a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by the Japanese company and AstraZeneca. 18 October 2025
Pharmaceutical
Germany’s Merck KGaA has presented longer-term results from the global Phase III MANEUVER trial evaluating pimicotinib at the European Society for Medical Oncology (ESMO) Congress 2025 now taking place in Berlin, Germany. 18 October 2025
Biotechnology
DESTINY-Breast05 Phase III trial data has shown that Enhertu (trastuzumab deruxtecan) led to a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment in HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and a high risk of disease recurrence. 18 October 2025
Pharmaceutical
Isotope Technologies Munich (ITM) has announced a higher objective response rate (ORR) and prolonged median progression-free survival (mPFS) across subgroups in patients treated with non-carrier-added (nca) 177Lu-edotreotide—also known as ITM-11 or 177Lu-edotreotide—compared to everolimus from its Phase III COMPETE trial in Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 18 October 2025
Biotechnology
Anglo-Swedish pharma major AstraZeneca has presented new data showing the impact of its PD-L1 inhibitor Imfinzi (durvalumab) in early cancer settings at the ongoing ESMO Annual Meeting. 17 October 2025
Biotechnology
US pharma major Eli Lilly has announced results from the primary overall survival (OS) analysis of the Phase III monarchE trial through a publication in the Annals of Oncology and a late-breaking oral presentation at the ESMO Annual Meeting. 17 October 2025
Live
Welcome to The Pharma Letter’s real-time coverage of the 2025 European Society of Medical Oncology (ESMO) Congress, taking place October 17 to 21. Our team is on site in Berlin, Germany, and this feed will deliver concise updates as they happen—check back here regularly for headline trial results, regulatory milestones, practice updates and more. 15 October 2025
Pharmaceutical
If recent top-line reads deliver on the big stage, this week's ESMO 2025 could re-draw standards across breast, genitourinary, gynaecologic and colorectal cancers—powered by three recurring themes: ADCs stepping earlier, radioligand therapy moving upstream and immuno-oncology showing life beyond metastatic niches. 14 October 2025
Biotechnology
US biotech Arcus Biosciences and partner Gilead Sciences have unveiled encouraging survival data for domvanalimab in gastric cancer, with new results presented in a mini oral session at the ESMO 2025 Congress. 14 October 2025
Pharmaceutical
AstraZeneca and Daiichi Sankyo have unveiled new Phase III results showing that Enhertu (trastuzumab deruxtecan) outperformed Roche’s Kadcyla (trastuzumab emtansine) in patients with high-risk HER2-positive early breast cancer. 29 September 2025
Pharmaceutical
Presentations at the European Society for Medical Oncology (ESMO) Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer cachexia, a life-threatening wasting condition in cancer patients. Belgo-American drug developer iTeos Therapeutics announced mixed data at ESMO on its anti-TIGIT belrestotug, under development with UK pharma major GSK. Also of note, Germany’s BioNTech presented mid-stage at ESMO for its BNT327 in lung cancer. In other significant developments, Organon announced it is acquiring Roivant Sciences subsidiary Dermavant for up to $1.2 billion, but only $175 million upfront. Denmark’s Novo Nordisk released Phase IIa results for its recently-acquired obesity candidate monlunabant. 22 September 2024
Biotechnology
US biotech major Regeneron has shown that the addition of its investigational LAG-3 inhibitor fianlimab to its PD-1 inhibitor Libtayo (cemiplimab) offers impressive results in advanced melanoma. 17 September 2024
Biotechnology
A cancer drug in-licensed by German biotech major BioNTech from China-based Biotheus could be a good one, if mid-stage results shared at the European Society for Medical Oncology (ESMO) are anything to go by. 17 September 2024
Biotechnology
Eisai and Merck & Co have announced positive data for their combination therapy of Lenvima (lenvatinib) and Keytruda (pembrolizumab) in liver cancer. 17 September 2024
Biotechnology
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024 16 September 2024
Pharmaceutical
German pharma major Bayer today released results from the Phase III ARANOTE trial at the European Society for Medical Oncology (ESMO) taking place in Spain. 16 September 2024
Biotechnology
Germany-based Immatics has this month announced updated clinical data from its PRAME-directed TCR T-cell therapy, anzu-cel (anzutresgene autoleucel, IMA203), in 16 patients with metastatic uveal melanoma. 3 November 2025
Biotechnology
US biotech Exelixis has announced detailed results from STELLAR-303, a global Phase III pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq) versus regorafenib in previously-treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). 20 October 2025
Pharmaceutical
Swiss pharma giant Novartis yesterday presented positive new Pluvicto (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025. 20 October 2025
Biotechnology
Positive results have been presented on Datroway (datopotamab deruxtecan) from the TROPION-Breast02 Phase III trial at the ESMO Annual Meeting in Berlin, Germany. 19 October 2025
Biotechnology
More positive data has been presented at the ESMO Congress on Enhertu (trastuzumab deruxtecan), a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by the Japanese company and AstraZeneca. 18 October 2025
Pharmaceutical
Germany’s Merck KGaA has presented longer-term results from the global Phase III MANEUVER trial evaluating pimicotinib at the European Society for Medical Oncology (ESMO) Congress 2025 now taking place in Berlin, Germany. 18 October 2025
Biotechnology
DESTINY-Breast05 Phase III trial data has shown that Enhertu (trastuzumab deruxtecan) led to a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment in HER2 positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and a high risk of disease recurrence. 18 October 2025
Pharmaceutical
Isotope Technologies Munich (ITM) has announced a higher objective response rate (ORR) and prolonged median progression-free survival (mPFS) across subgroups in patients treated with non-carrier-added (nca) 177Lu-edotreotide—also known as ITM-11 or 177Lu-edotreotide—compared to everolimus from its Phase III COMPETE trial in Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 18 October 2025
Biotechnology
Anglo-Swedish pharma major AstraZeneca has presented new data showing the impact of its PD-L1 inhibitor Imfinzi (durvalumab) in early cancer settings at the ongoing ESMO Annual Meeting. 17 October 2025
Biotechnology
US pharma major Eli Lilly has announced results from the primary overall survival (OS) analysis of the Phase III monarchE trial through a publication in the Annals of Oncology and a late-breaking oral presentation at the ESMO Annual Meeting. 17 October 2025
Live
Welcome to The Pharma Letter’s real-time coverage of the 2025 European Society of Medical Oncology (ESMO) Congress, taking place October 17 to 21. Our team is on site in Berlin, Germany, and this feed will deliver concise updates as they happen—check back here regularly for headline trial results, regulatory milestones, practice updates and more. 15 October 2025
Pharmaceutical
If recent top-line reads deliver on the big stage, this week's ESMO 2025 could re-draw standards across breast, genitourinary, gynaecologic and colorectal cancers—powered by three recurring themes: ADCs stepping earlier, radioligand therapy moving upstream and immuno-oncology showing life beyond metastatic niches. 14 October 2025
Biotechnology
US biotech Arcus Biosciences and partner Gilead Sciences have unveiled encouraging survival data for domvanalimab in gastric cancer, with new results presented in a mini oral session at the ESMO 2025 Congress. 14 October 2025
Pharmaceutical
AstraZeneca and Daiichi Sankyo have unveiled new Phase III results showing that Enhertu (trastuzumab deruxtecan) outperformed Roche’s Kadcyla (trastuzumab emtansine) in patients with high-risk HER2-positive early breast cancer. 29 September 2025
Pharmaceutical
Presentations at the European Society for Medical Oncology (ESMO) Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer cachexia, a life-threatening wasting condition in cancer patients. Belgo-American drug developer iTeos Therapeutics announced mixed data at ESMO on its anti-TIGIT belrestotug, under development with UK pharma major GSK. Also of note, Germany’s BioNTech presented mid-stage at ESMO for its BNT327 in lung cancer. In other significant developments, Organon announced it is acquiring Roivant Sciences subsidiary Dermavant for up to $1.2 billion, but only $175 million upfront. Denmark’s Novo Nordisk released Phase IIa results for its recently-acquired obesity candidate monlunabant. 22 September 2024
Biotechnology
US biotech major Regeneron has shown that the addition of its investigational LAG-3 inhibitor fianlimab to its PD-1 inhibitor Libtayo (cemiplimab) offers impressive results in advanced melanoma. 17 September 2024
Biotechnology
A cancer drug in-licensed by German biotech major BioNTech from China-based Biotheus could be a good one, if mid-stage results shared at the European Society for Medical Oncology (ESMO) are anything to go by. 17 September 2024
Biotechnology
Eisai and Merck & Co have announced positive data for their combination therapy of Lenvima (lenvatinib) and Keytruda (pembrolizumab) in liver cancer. 17 September 2024
Biotechnology
Swiss pharma giant has shared a well-timed updated analysis from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2024 16 September 2024
Pharmaceutical
German pharma major Bayer today released results from the Phase III ARANOTE trial at the European Society for Medical Oncology (ESMO) taking place in Spain. 16 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze